We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+18.58%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$115M
AUM Growth
+$7.3M
Cap. Flow
-$5.59M
Cap. Flow %
-4.84%
Top 10 Hldgs %
66.83%
Holding
65
New
5
Increased
9
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$2.5M
2
EQT icon
EQT Corp
EQT
+$1.18M
3
ATEC icon
Alphatec Holdings
ATEC
+$844K
4
CSTL icon
Castle Biosciences
CSTL
+$611K
5
KALV
KalVista Pharmaceuticals
KALV
+$453K

Top Sells

Rank Stock Value
1
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$4.27M
2
HROW icon
Harrow
HROW
+$2.61M
3
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
+$1.73M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$1.65M
5
OVV icon
Ovintiv
OVV
+$951K

Sector Composition

Rank Sector Weight
1 Healthcare 97.17%
2 Energy 2.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$35.5M 30.74%
686,182
-2,036
-0.3% -$95.5K
BDSX icon
2
Biodesix
BDSX
$209M
$10.1M 8.77%
284,806
– –
ACAD icon
3
Acadia Pharmaceuticals
ACAD
$4.38B
$6.16M 5.33%
400,400
+150,000
+60% +$2.5M
ELUT icon
4
Elutia
ELUT
$42M
$5.03M 4.36%
1,321,215
-230,440
-15% -$899K
UTHR icon
5
United Therapeutics
UTHR
$22.7B
$3.58M 3.1%
10,000
– –
PRTA icon
6
Prothena Corp
PRTA
$453M
$3.51M 3.04%
209,574
+6,000
+3% +$129K
NBIX icon
7
Neurocrine Biosciences
NBIX
$17.2B
$3.48M 3.02%
30,240
-12,000
-28% -$1.65M
CORT icon
8
Corcept Therapeutics
CORT
$9.72B
$3.42M 2.97%
74,000
– –
HROW icon
9
Harrow
HROW
$1.74B
$3.28M 2.84%
72,910
-77,090
-51% -$2.61M
QDEL icon
10
QuidelOrtho
QDEL
$1.19B
$3.08M 2.67%
67,619
– –
FHTX icon
11
Foghorn Therapeutics
FHTX
$305M
$2.99M 2.59%
320,930
– –
AXGN icon
12
Axogen
AXGN
$2.12B
$2.76M 2.39%
197,000
– –
PHR icon
13
Phreesia
PHR
$662M
$2.61M 2.26%
114,700
– –
STOK icon
14
Stoke Therapeutics
STOK
$1.81B
$2.58M 2.23%
210,000
– –
PTGX icon
15
Protagonist Therapeutics
PTGX
$9.06B
$2.16M 1.87%
48,000
– –
TVTX icon
16
Travere Therapeutics
TVTX
$5.27B
$2.07M 1.79%
148,000
+26,000
+21% +$271K
MASI
17
DELISTED
Masimo
MASI
$2.04M 1.76%
15,280
– –
OVV icon
18
Ovintiv
OVV
$16.2B
$2M 1.73%
52,200
-22,000
-30% -$951K
DCGO icon
19
DocGo
DCGO
$64.3M
$1.71M 1.48%
515,000
+55,000
+12% +$187K
CSTL icon
20
Castle Biosciences
CSTL
$733M
$1.65M 1.43%
58,000
+24,000
+71% +$611K
ALKS icon
21
Alkermes
ALKS
$8.79B
$1.4M 1.21%
50,000
– –
EQT icon
22
EQT Corp
EQT
$31B
$1.27M 1.1%
+34,619
New +$1.18M
ATEC icon
23
Alphatec Holdings
ATEC
$1.31B
$1.1M 0.95%
198,000
+110,000
+125% +$844K
KALV
24
DELISTED
KalVista Pharmaceuticals
KALV
$950K 0.82%
82,000
+36,000
+78% +$453K
KNSA icon
25
Kiniksa Pharmaceuticals
KNSA
$4.92B
$750K 0.65%
30,000
– –
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Birchview Capital held 65 positions worth $115M, up 6.7% from $108M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Birchview Capital withdrew a net $5.59M in Q3 2024, closing 4 positions and reducing 7 holdings. Its most notable exit was Silk Road Medical, Inc. Common Stock, an estimated $4.27M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Energy.

Against the trend, Birchview Capital opened a new position in EQT Corp worth $1.27M.

  • Birchview Capital's largest Q3 2024 buy was EQT Corp: 34,619 shares worth $1.27M.
  • Birchview Capital added most to Acadia Pharmaceuticals in Q3 2024, an estimated $2.5M increase.
  • Birchview Capital's biggest Q3 2024 reduction was Harrow, cutting an estimated $2.61M.
  • Birchview Capital fully exited Silk Road Medical, Inc. Common Stock in Q3 2024, selling an estimated $4.27M.
  • Birchview Capital's ten largest holdings make up 67% of its $115M portfolio in Q3 2024.
  • Birchview Capital opened 5 new positions and closed 4 in Q3 2024.
  • Birchview Capital's portfolio value rose 6.7% quarter-over-quarter to $115M.

Based on Birchview Capital's 13F filing for Q3 2024, filed 14 Nov 2024.